JCR: Journal of Clinical Rheumatology最新文献

筛选
英文 中文
Accuracy and Performance Characteristics of Administrative Codes for the Diagnosis of Autoinflammatory Syndromes: A Discovery and Validation Study. 诊断自身炎症综合征的行政代码的准确性和性能特征:一项发现和验证研究。
IF 2.4 4区 医学
JCR: Journal of Clinical Rheumatology Pub Date : 2024-11-15 DOI: 10.1097/RHU.0000000000002172
Saeyun Lee, Sujin Kim, Suzanne Segerstrom, Polly J Ferguson, Aleksander Lenert
{"title":"Accuracy and Performance Characteristics of Administrative Codes for the Diagnosis of Autoinflammatory Syndromes: A Discovery and Validation Study.","authors":"Saeyun Lee, Sujin Kim, Suzanne Segerstrom, Polly J Ferguson, Aleksander Lenert","doi":"10.1097/RHU.0000000000002172","DOIUrl":"https://doi.org/10.1097/RHU.0000000000002172","url":null,"abstract":"<p><strong>Objective: </strong>The aim of this study was to evaluate and validate the accuracy and performance characteristics of administrative codes in diagnosing autoinflammatory syndromes (AISs).</p><p><strong>Methods: </strong>We identified potential AIS patients from the electronic medical records at the University of Iowa Hospital and Clinics and the Stead Family Children's Hospital using a screening filter based on the 10th edition of the International Classification of Diseases (ICD-10) codes and interleukin-1 antagonists. Diagnostic criteria for adult-onset Still disease, systemic juvenile idiopathic arthritis, Behçet disease (BD), familial Mediterranean fever (FMF), cryopyrin-associated periodic syndrome (CAPS), and SAPHO (synovitis, acne, pustulosis, hyperostosis, and osteitis) syndrome and chronic nonbacterial osteomyelitis (SAPHO-CNO) were reviewed for each patient. Patients who did not meet the diagnostic criteria were categorized as non-AIS. In this cross-sectional study, we calculated the sensitivity, specificity, positive predictive value, negative predictive value, and area under the receiver operating characteristic curve for the ICD codes in diagnosing AIS.</p><p><strong>Results: </strong>Out of the 502 patients with potential AIS, 338 patients (67%) had a true AIS diagnosis. Sensitivity ranged from 80% (SAPHO-CNO) to 100% (BD and FMF), and positive predictive value ranged from 15% (FMF) to 80% (SAPHO-CNO). Specificity ranged from 81% (FMF) to 99% (CAPS and SAPHO-CNO), whereas negative predictive value ranged from 98% (adult-onset Still disease) to 100% (systemic juvenile idiopathic arthritis, BD, FMF, and CAPS). All ICD codes or code combinations for the diagnosis of specific AIS subtypes showed high accuracy with areas under the receiver operating characteristic curve ≥0.89.</p><p><strong>Conclusions: </strong>This study validated the accuracy of administrative codes for diagnosing AIS, supporting their use in constructing AIS cohorts for clinical outcomes research.</p>","PeriodicalId":14745,"journal":{"name":"JCR: Journal of Clinical Rheumatology","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143005526","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Neuro-IgG4-Related Inflammatory Pseudotumor. 神经IgG4相关炎性假瘤
IF 2.4 4区 医学
JCR: Journal of Clinical Rheumatology Pub Date : 2024-11-11 DOI: 10.1097/RHU.0000000000002158
Hirotaka Yamamoto, Yoshinori Taniguchi
{"title":"Neuro-IgG4-Related Inflammatory Pseudotumor.","authors":"Hirotaka Yamamoto, Yoshinori Taniguchi","doi":"10.1097/RHU.0000000000002158","DOIUrl":"https://doi.org/10.1097/RHU.0000000000002158","url":null,"abstract":"","PeriodicalId":14745,"journal":{"name":"JCR: Journal of Clinical Rheumatology","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142620732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Persistence of Biologic Therapies for Psoriatic Arthritis: A Narrative Review. 银屑病关节炎生物疗法的持久性:叙述性综述。
IF 2.4 4区 医学
JCR: Journal of Clinical Rheumatology Pub Date : 2024-11-11 DOI: 10.1097/RHU.0000000000002159
Magdalena Jasmen, Dominga García, Sebastián Ibáñez, Pamela Díaz
{"title":"The Persistence of Biologic Therapies for Psoriatic Arthritis: A Narrative Review.","authors":"Magdalena Jasmen, Dominga García, Sebastián Ibáñez, Pamela Díaz","doi":"10.1097/RHU.0000000000002159","DOIUrl":"https://doi.org/10.1097/RHU.0000000000002159","url":null,"abstract":"<p><strong>Abstract: </strong>Drug persistence is a crucial measure of long-term efficacy, safety, and patient satisfaction. Lack of persistence can increase healthcare costs and morbidity and mortality rates. This review aimed to consolidate available data on drug persistence for various biological treatments used as the primary intervention for psoriatic arthritis and identify factors associated with nonpersistence. Reports indicate variable 1-year persistence rates for biologic therapies, ranging from 37% to 73%. Specifically, tumor necrosis factor inhibitors have shown fluctuating 1-year persistence rates ranging from 32% to 85%. IL-12/23 and IL-23 inhibitors demonstrate persistence rates of 25% to 89%, whereas data for IL-17 and JAK inhibitors are more limited, ranging from 51% to 77%. Factors such as female sex and a higher burden of comorbidities have been associated with an increased risk of nonpersistence, although evidence regarding other factors remains scarce. The significant variability in reported persistence rates may be attributed to differences in treatment gaps and methodologies across studies. Addressing and mitigating the factors leading to nonpersistence is essential for improving treatment outcomes in psoriatic arthritis.</p>","PeriodicalId":14745,"journal":{"name":"JCR: Journal of Clinical Rheumatology","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142620761","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reproductive Health in Scleroderma, Vasculitis, and Sjögren Syndrome. 硬皮病、血管炎和斯约格伦综合症患者的生殖健康。
IF 2.4 4区 医学
JCR: Journal of Clinical Rheumatology Pub Date : 2024-10-01 DOI: 10.1097/RHU.0000000000002128
Francesca Crisafulli, Maria Grazia Lazzaroni, Cecilia Nalli, Rossana Orabona, Franco Franceschini, Angela Tincani
{"title":"Reproductive Health in Scleroderma, Vasculitis, and Sjögren Syndrome.","authors":"Francesca Crisafulli, Maria Grazia Lazzaroni, Cecilia Nalli, Rossana Orabona, Franco Franceschini, Angela Tincani","doi":"10.1097/RHU.0000000000002128","DOIUrl":"10.1097/RHU.0000000000002128","url":null,"abstract":"<p><strong>Abstract: </strong>Women with systemic chronic inflammatory disease, such as those with scleroderma, systemic vasculitis, and Sjögren syndrome, need preconception evaluation by a multidisciplinary team. Counseling and pregnancy management should be tailored to patients' needs, considering specific disease features, organ involvement, treatment options, and risk factors to minimize risks of maternal-fetal complications during pregnancy.Additionally, considerations regarding fertility, assisted reproductive techniques, and contraception also need to be addressed for these women.In this narrative review, we integrate the current published literature with our expert opinion to address the issues faced by patients with the aforementioned inflammatory conditions.</p>","PeriodicalId":14745,"journal":{"name":"JCR: Journal of Clinical Rheumatology","volume":"30 7S Suppl 1","pages":"S49-S55"},"PeriodicalIF":2.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11462880/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142347011","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lumbar Epidural Corticosteroid Injection-Induced Epidural Lipomatosis. 腰部硬膜外皮质类固醇注射引起的硬膜外脂肪瘤病。
IF 2.4 4区 医学
JCR: Journal of Clinical Rheumatology Pub Date : 2024-10-01 Epub Date: 2024-08-28 DOI: 10.1097/RHU.0000000000002126
Georges Hayek, Maud Creze
{"title":"Lumbar Epidural Corticosteroid Injection-Induced Epidural Lipomatosis.","authors":"Georges Hayek, Maud Creze","doi":"10.1097/RHU.0000000000002126","DOIUrl":"10.1097/RHU.0000000000002126","url":null,"abstract":"","PeriodicalId":14745,"journal":{"name":"JCR: Journal of Clinical Rheumatology","volume":" ","pages":"e164"},"PeriodicalIF":2.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142080240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Treatment Patterns for End-stage Kidney Failure in Patients with Systemic Lupus Erythematous: Erratum. 系统性红斑狼疮患者终末期肾衰竭的治疗模式:勘误。
IF 2.4 4区 医学
JCR: Journal of Clinical Rheumatology Pub Date : 2024-10-01 DOI: 10.1097/RHU.0000000000002153
{"title":"Treatment Patterns for End-stage Kidney Failure in Patients with Systemic Lupus Erythematous: Erratum.","authors":"","doi":"10.1097/RHU.0000000000002153","DOIUrl":"https://doi.org/10.1097/RHU.0000000000002153","url":null,"abstract":"","PeriodicalId":14745,"journal":{"name":"JCR: Journal of Clinical Rheumatology","volume":"30 7","pages":"301"},"PeriodicalIF":2.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142347005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Refractory Pneumonitis in Rheumatoid Arthritis: Pulmonary Mucosa-Associated Lymphoid Tissue Lymphoma. 类风湿性关节炎的难治性肺炎:肺粘膜相关淋巴组织淋巴瘤。
IF 2.4 4区 医学
JCR: Journal of Clinical Rheumatology Pub Date : 2024-10-01 Epub Date: 2024-08-28 DOI: 10.1097/RHU.0000000000002129
Hirotaka Yamamoto, Yoshinori Taniguchi
{"title":"Refractory Pneumonitis in Rheumatoid Arthritis: Pulmonary Mucosa-Associated Lymphoid Tissue Lymphoma.","authors":"Hirotaka Yamamoto, Yoshinori Taniguchi","doi":"10.1097/RHU.0000000000002129","DOIUrl":"10.1097/RHU.0000000000002129","url":null,"abstract":"","PeriodicalId":14745,"journal":{"name":"JCR: Journal of Clinical Rheumatology","volume":" ","pages":"e165"},"PeriodicalIF":2.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142080370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Safety of Medications Used to Treat Autoimmune Rheumatic Diseases During Pregnancy and Lactation. 孕期和哺乳期治疗自身免疫性风湿病药物的安全性。
IF 2.4 4区 医学
JCR: Journal of Clinical Rheumatology Pub Date : 2024-10-01 DOI: 10.1097/RHU.0000000000002123
Caroline H Siegel, Lisa R Sammaritano
{"title":"Safety of Medications Used to Treat Autoimmune Rheumatic Diseases During Pregnancy and Lactation.","authors":"Caroline H Siegel, Lisa R Sammaritano","doi":"10.1097/RHU.0000000000002123","DOIUrl":"https://doi.org/10.1097/RHU.0000000000002123","url":null,"abstract":"<p><strong>Abstract: </strong>Autoimmune rheumatic diseases (ARDs) often affect women during their reproductive years, and early studies of pregnancy in these patients reported high rates of adverse outcomes. Continuation or initiation of safe and effective medications in the preconception period is beneficial for maintaining or achieving disease quiescence throughout pregnancy thereby improving both maternal and pregnancy outcomes. The European Alliance of Associations for Rheumatology, the American College of Rheumatology, and the British Society for Rheumatology have published recommendations and guidelines regarding management of ARDs during pregnancy. The American College of Obstetricians and Gynecologists and the American Gastroenterological Association have also provided guidance statements with relevant recommendations. This review provides an overview of available recommendations for medication use in ARD pregnancy, with discussion of safety considerations for maternal and fetal well-being. Medications considered compatible with pregnancy include hydroxychloroquine, sulfasalazine, azathioprine, cyclosporine, tacrolimus, and TNF inhibitors. Methotrexate, mycophenolate, leflunomide, and cyclophosphamide should be avoided before and during pregnancy. Other medications, most of them newer, are largely discouraged for use in pregnancy due to inadequate data or concerns for neonatal immunosuppression, including non-TNF biologics and small molecule therapies. Further investigation is needed regarding effects of non-TNF biologics, biosimilars, and small molecules in pregnancy. Important efforts for the future will include improved methodologies to gather critical safety data, with consideration of inclusion of pregnant women in clinical trials, a complex and controversial issue. Long-term information on outcomes in offspring of treated women is lacking for many of these medications.</p>","PeriodicalId":14745,"journal":{"name":"JCR: Journal of Clinical Rheumatology","volume":"30 7S Suppl 1","pages":"S25-S33"},"PeriodicalIF":2.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142347013","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Vedolizumab, an α4β7-Integrin Inhibitor, Exacerbates Ulcerative Colitis-Related Spondylitis. α4β7-胰岛素抑制剂 Vedolizumab 会加重溃疡性结肠炎相关性脊柱炎。
IF 2.4 4区 医学
JCR: Journal of Clinical Rheumatology Pub Date : 2024-10-01 Epub Date: 2024-07-10 DOI: 10.1097/RHU.0000000000002114
Hirotaka Yamamoto, Yoshinori Taniguchi
{"title":"Vedolizumab, an α4β7-Integrin Inhibitor, Exacerbates Ulcerative Colitis-Related Spondylitis.","authors":"Hirotaka Yamamoto, Yoshinori Taniguchi","doi":"10.1097/RHU.0000000000002114","DOIUrl":"10.1097/RHU.0000000000002114","url":null,"abstract":"","PeriodicalId":14745,"journal":{"name":"JCR: Journal of Clinical Rheumatology","volume":" ","pages":"e161"},"PeriodicalIF":2.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141563432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cutaneous IgG4-Related Disease. 皮肤 IgG4 相关疾病。
IF 2.4 4区 医学
JCR: Journal of Clinical Rheumatology Pub Date : 2024-10-01 Epub Date: 2024-07-16 DOI: 10.1097/RHU.0000000000002113
Hirotaka Yamamoto, Yoshinori Taniguchi
{"title":"Cutaneous IgG4-Related Disease.","authors":"Hirotaka Yamamoto, Yoshinori Taniguchi","doi":"10.1097/RHU.0000000000002113","DOIUrl":"10.1097/RHU.0000000000002113","url":null,"abstract":"","PeriodicalId":14745,"journal":{"name":"JCR: Journal of Clinical Rheumatology","volume":" ","pages":"e160"},"PeriodicalIF":2.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141619921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信